Myasthenia gravis: Pathogenese, Diagnostik und Therapie

Literatur

• 1 Toyka K V, Drachman D B, Pestronk A, Kao I. Myasthenia gravis. Passive transfer from man to mouse.  Science. 1975;  190 397-399
• 2 Hohlfeld R, Melms A, Schneider C, Toyka K V, Drachman D B. Therapy of myasthenia gravis and myasthenic syndromes. In: Brandt T, Caplan LR, Dichgans J, Diener HC, Kennard C (Hrsg). Neurological disorders - course and treatment. Amsterdam: Elsevier 2003: 1341-1362
• 3 Hill M. The neuromuscular junction disorders.  J Neurol Neurosurg and Psychiatry. 2003;  74 (Suppl II) 32-37
• 4 Hoch W, McConville J, Helms S, Newsom-Davis J, Melms A, Vincent A. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies.  Nat Med. 2001;  7 365-368
• 5 Vincent A, Bowen J, Newsom-Davis J, McConville J. Seronegative generalised myasthenia gravis: clinical features, antibodies and their targets.  Lancet Neurology. 2003;  2 99-1065
• 6 Masaoka A, Monden Y, Nakahara K, Tanioka T. Follow-up study of thymoma with special reference to their clinical stages.  Cancer. 1981;  48 2485-2492
• 7 Hohlfeld R, Wekerle H. The immunopathogenesis of myasthenia gravis.  In: Engel AG (Hrsg.). Myasthenia gravis and myasthenic syndromes. Oxford: Oxford University Press 1999: 87-110
• 8 Buckley C, Newsom-Davis J, Willcox N, Vincent A. Do titin and cytokine antibodies predict thymoma and thymoma recurrence?.  Neurology. 2001;  57 1579-1582
• 9 Batocchi A P, Majolini L, Evoli A, Lino M M, Minisci C, Tonali P. Course and treatment of myasthenia gravis during pregnancy.  Neurology. 1999;  52 447-452
• 10 Osserman K E, Genkins G. Studies in myasthenia gravis: review of a twenty-year experience in over 1200 patients.  Mt Sinai J Med. 1971;  38 497-537
• 11 Besinger U A, Toyka K V, Homberg M, Heininger K, Hohlfeld R, Fateh-Moghadam A. Myasthenia gravis: long-term correlation of binding and bungarotoxin blocking antibodies against acetylcholine receptors with changes in disease severity.  Neurology. 1983;  33 1316-1321
• 12 Burns T M, Russell J A, LaChance D H, Jones H R. Oculobulbar involvement is typical with Lambert-Eaton Myasthenic Syndrome.  Ann Neurol. 2003;  53 270-273
• 13 Schneider C, Reiners K. Elektrophysiologische Diagnostik neuromuskulärer Übertragungsstörungen.  Klin Neurophysiol. 2000;  31 122-135
• 14 Lindstrom J. An assay for antibodies to human acetylcholine receptor in serum from patients with myasthenia gravis.  Clin Immunol Immunopathol. 1977;  7 36-43
• 15 Marienhagen J, Schalke B, Aebert H, Held P, Eilles C, Bogdahn U. Somatostatin receptor scintigraphy in thymoma imaging method and clinical application.  Pathol Res Pract. 1999;  195 575-581
• 16 Michels M. Hohlfeld R, Hartung HP, Heininger K, Besinger UA, Toyka KV. Myasthenia gravis: discontinuation of longterm azathioprine.  Ann Neurol. 1988;  24 798
• 17 Drachman D B, Jones R J, Brodsky R A. Treatment of refractory myasthenia gravis: Rebooting with high dose cyclophosphamide.  Ann Neurol. 2003;  53 29-34
• 18 Ciafaloni E, Massey J M, Tucker-Lipscomb B, Sanders D B. Mycophenolate mofetil for myasthenia gravis: an open-label pilot study.  Neurology. 2001;  56 97-99
• 19 Schneider C, Gold R, Reiners K, Toyka K V. Mycophenolate mofetil in the therapy of severe myasthenia gravis.  Eur Neurol. 2001;  46 79-82
• 20 Heininger K, Hartung H P, Toyka K V, Gaczkowski A, Borberg H. Therapeutic plasma exchange in myasthenia gravis: semiselective adsorption of Anti-AChR autoantibodies with tryptophane-linked polyvinylalcohol gels.  Ann N Y Acad Sci. 1987;  505 898-900
• 21 Gajdos P, Chevret S, Clair B, Tranchant C, Chastang C. Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis.  Ann Neurology. 1997;  41 789-796
• 22 Flachenecker P, Taleghani B M, Gold R, Grossmann R, Wiebecke D, Toyka K V. Treatment of severe myasthenia gravis with protein A immunoadsorption and cyclophosphamide.  Transfus Sci. 1998;  19 (Suppl) 43-46
• 23 Gronseth G S, Barohn R J. Practice parameter: thymectomy for autoimmune myasthenia gravis (an evidence-based review).  Neurology. 2000;  55 7-15
• 24 Mayer S A. Intensive care of the myasthenic patient.  Neurology. 1997;  48 (Suppl.) 570-575
• 25 Thomas C E, Mayer S A, Gungor Y, Swarup R, Webster E A, Chang I, Branagan T H, Fink M E, Rowland L P. Myasthenic crisis: clinical features, mortality, complications and risk factors for prolonged intubation.  Neurology. 1997;  48 1253-1260